18,218 Shares in Merck & Co., Inc. $MRK Purchased by Hilton Head Capital Partners LLC

Key Points

• Hilton Head Capital Partners disclosed a new fourth-quarter stake in Merck, buying 18,218 shares worth about $1.9 million. The position makes Merck its 18th-largest holding and represents 1.1% of the fund’s portfolio.
• Merck continues to attract major institutional interest, with large investors such as Norges Bank, DLD Asset Management, Jennison Associates, Invesco, and Ameriprise also adding or increasing positions. Overall, institutional investors own 76.07% of the company’s stock.
• Recent company news has been broadly supportive: Merck settled more than $50 million in Gardasil-related lawsuits, shares moved above key short-term moving averages, and investor focus remains on its oncology pipeline and Keytruda growth. The stock was also up slightly, with analysts maintaining a Moderate Buy consensus and an average price target of $128.18.

Hilton Head Capital Partners LLC acquired a new stake in Merck & Co., Inc. (NYSE:MRK - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The fund acquired 18,218 shares of the company's stock, valued at approximately $1,918,000. Merck & Co., Inc. accounts for 1.1% of Hilton Head Capital Partners LLC's portfolio, making the stock its 18th largest holding.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Norges Bank bought a new stake in shares of Merck & Co., Inc. in the fourth quarter valued at approximately $3,997,933,000. DLD Asset Management LP boosted its holdings in Merck & Co., Inc. by 30.1% in the 3rd quarter. DLD Asset Management LP now owns 47,500,000 shares of the company's stock worth $3,986,675,000 after buying an additional 11,000,000 shares during the period. Jennison Associates LLC purchased a new position in Merck & Co., Inc. in the 4th quarter valued at approximately $585,192,000. Invesco Ltd. grew its stake in Merck & Co., Inc. by 16.6% in the 3rd quarter. Invesco Ltd. now owns 19,844,936 shares of the company's stock valued at $1,665,585,000 after buying an additional 2,821,766 shares in the last quarter. Finally, Ameriprise Financial Inc. raised its holdings in Merck & Co., Inc. by 20.7% during the 3rd quarter. Ameriprise Financial Inc. now owns 15,933,909 shares of the company's stock valued at $1,336,877,000 after acquiring an additional 2,735,459 shares during the period. Institutional investors own 76.07% of the company's stock.

Merck & Co., Inc. News Summary

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck reached a settlement of more than $50 million to resolve over 200 Gardasil-related lawsuits, removing a significant legal overhang and helping investors refocus on the company’s core business and pipeline. Merck Gardasil Settlement Eases Legal Overhang And Refocuses Investor Attention
• Positive Sentiment: Merck recently broke above both its 20-day and 50-day moving averages, a technical signal that traders often view as a sign of improving short-term momentum. Merck (MRK) Recently Broke Out Above the 20-Day Moving Average
• Positive Sentiment: Merck’s oncology franchise continues to draw attention after ASCO 2026 updates highlighted Keytruda’s strength in solid tumors and other pipeline assets aimed at offsetting future exclusivity pressure. ASCO26: Solid tumour data readouts outline Merck & Co’s oncology prowess
• Positive Sentiment: Merck’s collaboration with Moderna on a personalized mRNA cancer vaccine also got a boost from positive long-term data disclosed by Moderna, reinforcing investor interest in the partnership. Why Is Moderna (MRNA) Stock Rocketing Higher Today
• Neutral Sentiment: Merck’s conference appearance and oncology strategy update likely kept investor focus on the pipeline, but the items available do not indicate a major new catalyst beyond ongoing progress. Merck & Co., Inc. (MRK) Discusses Oncology Strategy and Program Update With Focus on Clinical Progress and Pipeline Diversification - Slideshow

Wall Street Analyst Weigh In

A number of research firms have recently commented on MRK. Royal Bank Of Canada reaffirmed an "outperform" rating and issued a $142.00 price target on shares of Merck & Co., Inc. in a report on Monday, March 30th. Citigroup started coverage on Merck & Co., Inc. in a research note on Wednesday, May 6th. They set a "neutral" rating and a $125.00 price objective on the stock. Weiss Ratings downgraded Merck & Co., Inc. from a "hold (c+)" rating to a "hold (c)" rating in a research note on Friday, May 15th. Wells Fargo & Company reduced their target price on Merck & Co., Inc. from $150.00 to $145.00 and set an "overweight" rating for the company in a report on Friday, May 1st. Finally, JPMorgan Chase & Co. upped their price target on Merck & Co., Inc. from $125.00 to $135.00 and gave the company an "overweight" rating in a research report on Monday, April 6th. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and seven have assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $128.18.

Merck & Co., Inc. Stock Up 0.2%

MRK opened at $121.05 on Monday. The firm has a market capitalization of $298.96 billion, a P/E ratio of 34.10, a price-to-earnings-growth ratio of 2.72 and a beta of 0.21. Merck & Co., Inc. has a one year low of $76.66 and a one year high of $125.14. The company has a fifty day moving average price of $116.55 and a 200-day moving average price of $112.52. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.06.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last issued its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.47) by $0.19. The company had revenue of $16.29 billion for the quarter, compared to the consensus estimate of $15.85 billion. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The firm's revenue was up 4.9% compared to the same quarter last year. During the same quarter last year, the business posted $2.22 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. Equities research analysts expect that Merck & Co., Inc. will post 5.17 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, July 8th. Stockholders of record on Monday, June 15th will be given a dividend of $0.85 per share. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date is Monday, June 15th. Merck & Co., Inc.'s dividend payout ratio (DPR) is 95.77%.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.